STOCK TITAN

Mannkind Corp - MNKD STOCK NEWS

Welcome to our dedicated news page for Mannkind (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mannkind's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mannkind's position in the market.

News
Rhea-AI Summary
MannKind (MNKD) has repaid its credit and security agreement with MidCap Financial Trust and convertible note issued to Mann Group in full, reducing total debt by approximately $41.8 million. The repayment includes $31.6 million to MidCap Financial Trust and exchange for 1.5 million shares of common stock and $8.9 million to Mann Group CEO Michael Castagna highlighted the elimination of expensive debt and undervaluation of the stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
-
News
Rhea-AI Summary
MannKind announces Steven B. Binder's retirement as CFO and the appointment of Christopher Prentiss as the new CFO. Binder will transition to Executive Vice President, Special Projects until the end of 2024. Prentiss brings over 20 years of financial leadership experience in the biopharma industry, having served in various finance positions in both private and public companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
none
-
Rhea-AI Summary
MannKind Corporation announces promising results from the INHALE-3 Phase 4 clinical trial, showing a significant reduction in post-meal hyperglycemia and glucose excursions with inhaled insulin compared to standard care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.52%
Tags
none
Rhea-AI Summary
MannKind Corporation (Nasdaq: MNKD) to present new clinical data from the INHALE-3 study at the ATTD Conference. Dr. Hirsch will discuss results of switching from MDI or insulin pumps to inhaled insulin (Afrezza®). The study focuses on post-prandial glucose levels, hypoglycemia frequency, and mealtime control in T1D patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
-
Rhea-AI Summary
MannKind Corporation (MNKD) announced its participation in upcoming conferences to showcase its inhaled therapeutic products. The company will be presenting at Leerink Partners Global Biopharma Conference 2024 and Oppenheimer 34th Annual Healthcare MedTech & Services Conference. Interested parties can access the live webcast and replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
conferences
-
Rhea-AI Summary
MannKind Corporation reports impressive financial results for Q4 2023 and full year 2023 with total revenues of $199M, net income of $1M, and cash position of $302M. Positive revenue growth driven by Afrezza and collaborations. Clinical trials progressing well with upcoming data read-outs and FDA submissions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
Rhea-AI Summary
MannKind Corporation (MNKD) will announce its 2023 fourth quarter and full year financial results on February 27, 2024. The conference call will feature CEO Michael Castagna and CFO Steven Binder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
-
Rhea-AI Summary
MannKind Corporation (MNKD) has successfully enrolled 305 patients with diabetes in its INHALE-1 study to assess the efficacy and safety of inhaled insulin in the pediatric population. The primary endpoint analysis is expected in the fourth quarter of 2024, with data dissemination and FDA submission anticipated in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none
-
Rhea-AI Summary
MannKind Corporation (MNKD) sold a 1% royalty in net sales of Tyvaso DPI® to Sagard Healthcare for $150 million, with a potential milestone payment of up to $50 million. Tyvaso DPI is marketed by United Therapeutics Corporation for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease following U.S. FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
Rhea-AI Summary
MannKind Corporation (MNKD) CEO Michael Castagna to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
conferences
Mannkind Corp

Nasdaq:MNKD

MNKD Rankings

MNKD Stock Data

1.12B
265.99M
1.53%
50.18%
11.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Westlake Village

About MNKD

mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.